Abstract: Overexpression of P-glycoprotein (P-gp) in the brain is an important factor leading to drug-resistant epilepsy. Clinical use of P-gp inhibitors is limited by their systemic toxicity. In this study, we tested the hypothesis that FTY720, a sphingosine 1-phosphate (S1P) analogue used for treating multiple sclerosis, modulates the up-regulation of P-gp and improves brain delivery of phenytoin (PHT) through S1P receptor 1 in the hippocampus of a pilocarpine-induced rat model of status epilepticus (SE). We administered vehicle, FTY720 or FTY720+ W146 (an S1P receptor 1 antagonist) to SE rats. Forty-eight hours after SE, we dissected the hippocampus and measured P-gp expression, NF-jB activity and levels of inflammatory mediators (TNF-a and COX-2) by Western blotting and enzyme-linked immunosorbent assay. We also measured hippocampal and plasma concentrations of PHT 30, 60, 90, 120 and 180 min. after an intraperitoneal injection of PHT (50 mg/kg) 48 hr after SE, using microdialysis and high-performance liquid chromatography. FTY720 alleviated the overexpression of hippocampal P-gp in SE rats and reduced NF-jB activity and TNF-a and COX-2 expression, and W146 blocked the effects of FTY720. Furthermore, SE rats that received FTY720 showed significantly greater hippocampal extracellular PHT concentrations than those that received vehicle, and W146 abolished this effect. Our results suggest that FTY720 alleviates seizure-induced overexpression of P-gp by inhibiting S1P receptor 1-mediated inflammation in rat hippocampus and improves PHT delivery to brain. FTY720 shows potential as an adjuvant therapy for drug-resistant epilepsy.
More than 30% of people with epilepsy are resistant to pharmacotherapy despite large number of available antiepileptic drugs (AEDs) [1] . P-glycoprotein (P-gp) is considered an important mechanism in drug-resistant epilepsy as it is overexpressed at the blood-brain barrier (BBB) and mediates the efflux of different AEDs into the capillary lumen, thereby limiting their brain penetration and access to target sites [2, 3] . Selective inhibition of P-gp enhances brain uptake of AEDs and improves the therapeutic outcome in patients with drugresistant epilepsy and in rats [4] [5] [6] . However, clinical use of these P-gp inhibitors is limited by their systemic toxicity [7] .
The mechanisms underlying the overexpression of P-gp in the epileptic brain remain unclear. Mounting evidence indicates that neuroinflammation plays an important role in the modulation of P-gp. Suppression of NF-jB activity and its downstream inflammatory mediators, such as tumour necrosis factor-a (TNF-a) and cyclooxygenase-2 (COX-2), reduces the up-regulation of P-gp [8] [9] [10] [11] . In chronic epileptic rats, COX-2 inhibition restores P-gp overexpression and promotes brain delivery of AEDs, and reduces the frequency of spontaneous recurrent seizures [12] [13] [14] .
FTY720, a sphingosine 1-phosphate (S1P) analogue, has been recently approved by the US Food and Drug Administration for the treatment of relapsing-remitting multiple sclerosis (MS) because it can inhibit the egress of lymphocytes from lymph nodes, thereby preventing these pathogenic cells from migrating into the central nervous system (CNS) [15] . Additionally, FTY720 can cross BBB and has a direct effect on the neural cells that express abundant S1P receptors (S1PRs) [16] . FTY720 has anti-inflammatory properties in CNS diseases other than MS, such as ischaemic stroke [17] , Huntington's disease [18] , Alzheimer's disease [19] , epilepsy [20] and traumatic brain injury [21] . Reduction in NF-jB activity and downstream inflammatory mediators, such as TNF-a, induced nitric oxide synthase (iNOS) and COX-2, contributes to the anti-inflammatory action of FTY720 [18, 22] .
In previous studies, FTY720 suppressed P-gp activity in a multidrug-resistant human colon cancer cell line [23] , and in killifish tubules and rat brain capillaries, FTY720 and S1P decreased P-g transport activity in a S1PR1-dependent manner [24, 25] . However, it is unknown whether FTY720 FTY720 can inhibit seizure-induced P-gp overexpression in the brain.
Because FTY720 has anti-inflammatory effects and inhibits P-gp in vitro, we hypothesised that it would modulate seizureinduced overexpression of P-gp and increase brain delivery of AEDs. To test this hypothesis, we first examined whether FTY720 suppressed up-regulation of P-gp in rat hippocampus after pilocarpine-induced SE. Next, we determined whether the action of FTY720 on P-gp up-regulation was accompanied by a reduction in NF-jB activation and its downstream inflammatory mediators, COX-2 and TNF-a. Finally, we measured brain delivery of phenytoin (PHT), a first-line AED, to ensure reduction in P-gp activity after FTY720 administration. In addition, we tested whether FTY720 exerted these actions in an S1PR1-dependent manner.
Material and Methods
Animals. Male Sprague Dawley rats (200-220 g) were purchased from the Medical College of Xi'an Jiaotong University. The rats were housed in a controlled environment at 21 AE 1°C and 60% humidity, under a 12-hr light/dark cycle (lights on at 8:00 a.m.). Food and water were available ad libitum. All animal procedures were approved by the Ethics Committee of the First Affiliated Hospital of Xi'an Medical University and carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Establishment of SE. The rat SE model was established as described previously [20] . In brief, 18-20 hr after administration of lithium chloride (127 mg/kg i.p.; Sigma, St. Louis, MO, USA), rats were injected with scopolamine methyl bromide (1 mg/kg i.p.; Sigma). Pilocarpine (30 mg/kg i.p.; Sigma) was administered 30 min. later. Control rats received an equivalent volume of saline instead of pilocarpine. Seizure activity was monitored continuously and graded according to the Racine scale [26] . An animal was considered to be in SE when continuous generalised seizure activity was observed without normal behaviour being regained between seizure episodes. When rats had experienced SE for 90 min., the seizures were terminated using diazepam (10 mg/kg i.p., repeated after 3 min. if seizure activity continued). The SE rats were injected subcutaneously with 0.9% saline (10 ml per rat) to restore volume loss. All SE animals were given water-soaked food until they were able to eat normal dry food pellets.
Of the 72 rats that received pilocarpine, 68 developed SE and 13 died after SE. Control rats did not show any seizure-like behaviours.
Experimental design and tissue preparation. An overview of the experimental design is shown in fig. 1 . Experiment 1: control rats (n = 5) and SE rats (n = 5 per time-point: 6, 24, 48 hr, 3 days and 7 days after SE) were killed to confirm the changes in hippocampal P-gp expression over time after SE. Experiment 2: 20 rats were allocated to four groups (n = 5 rats per group), as follows: control; SE + Veh (SE rats received vehicle injection); SE + FTY (SE rats injected with FTY720; Cayman Chemicals, Ann Arbor, MI, USA); SE + FTY + W146 group (SE rats injected with FTY720 and W146; Cayman Chemicals). FTY720 was dissolved in 0.9% saline. W146 was dissolved in 1% dimethyl sulfoxide in 0.9% saline. FTY720 (1 mg/kg i.p.), W146 (10 mg/kg i.p.) and vehicle were administered immediately and once a day after termination of SE. These SE rats were killed 48 hr after SE. The dose of FTY720 was selected based on its efficacy against seizure-induced inflammation in rat brain [20] and safety for intraperitoneal administration [27] . Experiment 3: the rats were grouped as in Experiment 2. Fortyeight hours after SE, rats received PHT (50 mg/kg i.p.), and the plasma and dialysate in hippocampus were obtained 30, 60, 90, 120 and 180 min. after PHT injection.
The rats were decapitated and the brains were immediately removed on an ice plate. The hippocampus was quickly dissected for subsequent Western blotting and enzyme-linked immunosorbent assay (ELISA).
Western blot. Hippocampal protein levels of P-gp, nuclear NF-jB p65 and cytosolic phosphorylated inhibitor of kappa B alpha (p-IкBa)
were measured using Western blot analysis. In brief, the hippocampus samples were homogenised and lysed in RIPA buffer and centrifuged at 17,400 g for 10 min. at 4°C. The supernatant was aliquoted and stored at À70°C until needed. Nuclear and cytosolic proteins were extracted using the KeyGen Nuclear and Cytoplasmic Protein Extraction Kit (KeyGen Biotech Co. Ltd., Nanjing, China) according to the manufacturer's instructions. Protein concentrations were measured using a bicinchoninic acid protein assay. Protein samples were loaded onto SDS-polyacrylamide gels and transferred electrophoretically onto nitrocellulose membranes. After that, membranes were blocked in 2% BSA in phosphate-buffered saline on a rocking platform for 1 hr at room temperature followed by overnight incubation at 4°C with the primary antibodies. Blots were then incubated for 1 hr at room temperature with HRP-conjugated secondary antibodies. Protein bands were detected using an Enlight Western blotting detection reagent (Engreen Biosystem Co. Ltd., Beijing, China). Densitometry analysis of Western blots was performed using ImageJ software. The relative protein levels were calculated using b-actin or lamin B as the loading control.
The primary antibodies used were as follows: mouse monoclonal anti-P-gp (C-219; Gene Tex Inc, Irvine, CA, USA), rabbit anti-NF-jB p65 (1:200; Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-p-IjBa antibody (1:1000; Cell Signaling Technology, Danvers, MA, USA), mouse anti-b-actin monoclonal antibody (1:500; Santa Cruz Biotechnology) and mouse anti-Lamin-B monoclonal antibody (1:500; Santa Cruz Biotech). Secondary antibodies used were antimouse IgG (1:2000; Cell Signaling Technology) and anti-rabbit IgG (1:2000; Cell Signaling Technology).
ELISA. After weighing, the hippocampus was homogenized on ice using a tissue homogeniser and centrifuged at 7,700 g for 15 min. at 4°C. The supernatant was collected and stored at À70°C for subsequent analysis of COX-2 and TNF-a concentrations. Commercially available ELISA kits were used according to the Microdialysis and high-performance liquid chromatography (HPLC). Rats were anaesthetised with chloral hydrate (380 mg/kg i.p.), and the head was fixed in a stereotaxic apparatus (RWD Life Science Co, Ltd, Shenzhen, China). After measurement of PHT recovery rate, a CMA 12 microdialysis probe (3 mm polycarbonate membrane, 20 kD cut-off) was implanted into the left ventral hippocampus (from bregma: DV, 7.5; AP, À5.3; ML +5.0 mm) and Ringer's solution was infused into the probe for 2 hr (equilibration period). The inflow of Ringer's solution to the probe was driven by a microperfusion pump (CMA/100 microinjection pump; Carnegie Medicine, Stockholm, Sweden) with a 2 ll/min. flow rate. PHT (50 mg/kg i.p.) was administered, and the dialysate samples were collected at 30, 60, 90, 120 and 180 min. after injection. The extracellular PHT concentration in the hippocampus was calculated as the concentration in the dialysate/recovery rate. After microdialysis, the rat was decapitated and the brain was removed to histologically verify probe placement.
At 30, 60, 90, 120 and 180 min. after PHT injection, 0.3 ml blood was collected from the tail vein and centrifuged (17,400 g, 4°C) for 5 min. to obtain plasma. PHT concentrations in plasma and dialysate were determined using HPLC. According to the manufacturer's protocol, a 20 ll sample was prepared and injected into the chromatograph (MODEL 510; Syltech Scientific Instrument Co, Ltd, Beijing, China). The chromatographic conditions were as follows: ODS C18 column (200 9 4 mm, particle 10 lm); mobile phase: methanol/water (55:45, v: v); detection wavelength: 210 nm (ultraviolet).
Statistical analysis. All data were presented as the mean AE standard error of the mean (S.E.M.) and were analysed using IBM SPSS 22.0 (IBM SPSS, Chicago, IL, USA). One-way analysis of variance (ANOVA) followed by LSD post hoc comparison was used to analyse Western blot and ELISA data. PHT concentrations in plasma and dialysate were analysed using repeated-measures two-way ANOVA followed by Tukey's test. A value of p < 0.05 was considered statistically significant.
Results

Change in hippocampal P-gp expression after SE in rats.
To reveal the time characteristics of P-gp expression in the hippocampus of SE rats in our experimental conditions, we measured hippocampal P-gp at various time-points, by Western blotting. P-gp expression was up-regulated 6 hr after SE (p < 0.05 compared with control) and reached a peak at 48 hr, before decreasing to control level by 7 days after SE ( fig. 2) . We therefore selected 48 hr after SE as the time-point for subsequent experiments.
FTY720 attenuates overexpression of P-gp via S1PR1 in SE rat hippocampus. Hippocampal P-gp expression in the SE + FTY group was significantly lower than in the SE + Veh group (p < 0.01; fig. 3 ). We then examined whether S1PR1 was specifically involved in the suppressive effect of FTY720 on P-gp overexpression. W146, a selective antagonist of S1PR1, abated the effect of FTY720 on P-gp expression (p < 0.01, compared with SE + FTY; fig. 3 ). Together, these results suggest that activation of S1PR1 by FTY720 inhibits seizure-induced P-gp overexpression in rat hippocampus.
FTY720 suppresses NF-jB activity via S1PR1 in SE rat hippocampus. Previous studies indicated that NF-jB activation is involved in seizure-induced overexpression of P-gp [11] . To examine whether the NF-jB signalling pathway underlies the decrease in P-gp expression after FTY720 administration, we performed Western blot analysis for nuclear NF-jB p65 and cytoplasmic p-IкBa in the hippocampus. SE + FTY rats showed significantly lower expression levels of nuclear NF-jB p65 than SE + Veh rats (p < 0.01; fig. 4A, B) . Moreover, p-IкBa protein was strongly down-regulated in SE + FTY720 rats compared with SE + Veh rats (p < 0.01; fig. 4C, D) . In contrast, additional administration of W146 increased the expression of NFjB p65 and p-IкBa (both p < 0.01 compared with SE + FTY720; fig. 4 ). These results suggest that FT720 down-regulates P-gp expression in SE rats and that this effect is accompanied by S1PR1-dependent inhibition of NF-jB activity.
FTY720 alleviates TNF-a and COX-2 expression via S1PR1 in SE rat hippocampus. NF-jB regulates the expression of a large number of genes associated with neuroinflammation [28] . Pro-inflammatory factors, such as TNF-a and COX-2, induce overexpression of Pgp [12, 29] . Next, we examined whether the inhibitory action of FTY720 on P-gp overexpression correlated with decreased levels of TNF-a and COX-2 in the hippocampus of SE rats. There was a 3.2 time increase in TNF-a in vehicle-treated SE rats compared with control rats (p < 0.01; fig. 5A ). However, FTY720-treated SE rats showed strong down-regulation of TNF-a (p < 0.01 compared with SE + Veh rats; fig. 5A ). Furthermore, COX-2 expression was significantly reduced by FTY720 administration (p < 0.01, compared with SE + Veh rats; fig. 5B ). In SE rats that received FTY720 + W146, TNF-a and COX-2 were significantly greater than in FTY720-treated SE rats (both p < 0.01, fig. 5 ). These data indicate that FTY720 reduces the up-regulation of hippocampal TNF-a and COX-2 in a S1PR1-dependent manner in SE rats.
FTY720 strengthens extracellular PHT concentration in SE rat hippocampus. Considering that up-regulation of P-gp is one of the mechanisms that leads to resistance to multiple AEDs [30] , we investigated whether FTY720 strengthened brain delivery of PHT. PHT concentration in plasma in the control, SE + Veh, SE + FTY and SE + FTY + W146 groups showed no significant change 48 hr after SE (all p > 0.05, fig. 6A ). However, hippocampal extracellular PHT in SE rats was significantly lower than that in control rats (p < 0.05, fig. 6B ). In SE + FTY rats, the extracellular PHT level was significantly higher than in SE + Veh rats (p < 0.05, fig. 6B ), and this increase was abolished by additional W146 administration (p < 0.05, SE + FTY compared with SE + FTY + W146; fig. 6B ). These results indicate that activation of S1PR1 by FTY720 strengthens PHT transport from plasma to brain in the hippocampus of SE rats.
Discussion
The present work provides evidence that activation of S1PR1 by FTY720 inhibits seizure-induced overexpression of hippocampal P-gp in rats by suppressing up-regulation of NF-jB activity and its downstream inflammatory mediators, TNF-a and COX-2. Furthermore, FTY720 reduces the overexpression of P-gp associated with increased brain delivery of PHT, a first-line AED.
Pilocarpine-induced SE triggers a pronounced overexpression of P-gp in rodent brain and is widely used to study mechanisms of P-gp modulation [13, [31] [32] [33] [34] . In these studies, P-gp expression is measured at 24 or 48 hr after SE because there is significant up-regulation of P-gp at this time. In our condition, expression of P-gp increased 6 hr after SE, and peak expression occurred 48 hr post-SE. Seven days later, hippocampal P-gp expression returned to control level. These results closely agree with a previous report [35] .
The mechanism underlying seizure-induced P-gp overexpression remains poorly understood. A large body of evidence has shown that up-regulation of the NF-jB pathway and proinflammatory factors, including TNF-a and COX-2, can induce overexpression of P-gp in seizure rats [11, 36] . Potschka's group suggested that inhibition of COX-2 can attenuate abnormal expression of P-gp, strengthen brain delivery of AEDs and reduce seizure frequency in epileptic rats [13, 14, 33] . Besides NF-jB signalling, the p38 MAPK pathway might also be involved in regulating P-gp expression in refractory epilepsy [37] .
FTY720 activates all S1P receptors (S1PR1-S1PR5) except for S1PR2 [38] . Activation of S1PR1 is associated with reduced NF-jB signalling and pro-inflammatory mediators in IL-1b-induced inflammation in human chondrocytes [39] , which is in accordance with our results in brain. In a model of Alzheimer's disease, a specific S1PR1 inhibitor efficiently suppressed FTY720-ameliorating effects on COX-2 and TNFa expression [40] , also in agreement with our results. In addition, FTY720 prevented overactivation of NF-jB signalling and increase in TNF-a [18] in a mouse model of Huntington's disease. These lines of evidence demonstrate that FTY720 inhibits inflammation by S1PR1 activation and may down-regulate seizure-induced overexpression of P-gp in brain. In our results, suppression of P-gp by FTY720 was associated with a decrease in NF-jB activity and in levels of TNF-a and COX-2, which further suggests that NF-jB/TNF-a and COX-2 modulate seizure-induced P-gp overexpression. In SE model, both infiltrated inflammatory cells and resident cells in brain play important roles in the neuroinflammation [41, 42] . FTY720 prevents peripheral lymphocytes from migrating into the CNS and directly inhibits the activation of microglia and astrocytes in brain [15, 43] . Inhibition of innate and adaptive immune/ inflammation is probably involved in the effects of FTY720 on NF-jB activity and levels of TNF-a and COX-2.
However, a recent study reported that in the cardiomyocyte, FTY720 significantly inhibited S1P-mediated NF-jB activity and pro-inflammatory cytokine production by S1PR1 inhibition, instead of activation of S1PR1 [44] . FTY720 initially acts as an agonist of S1PRs, but chronic exposure to the drug leads to receptor internalisation and functional antagonism [45] . This characteristic of FTY720 may contribute to the opposing effects on S1PR1.
In killifish tubules and rat brain capillaries in vitro, FTY720 and S1P can decrease P-gp transport activity in an S1PR1-dependent manner [24, 25] . In the present in vivo experiment, blocking S1PR1 efficiently abolishes the effect of FTY720 on seizure-induced P-gp overexpression. S1PR1 activation might play an important role in P-gp regulation. However, one report suggests that FTY720 stimulates the activity of P-gp [46] . In those experiments, 5 lg/ml FTY720 substantially increased Pgp activity in T cells in vitro. The different effects of FTY720 on P-gp activity might be due to the different experimental paradigms and doses of FTY720 used.
P-gp overexpression decreases AED delivery to the brain, which leads to insufficient AED concentrations at the drug target site and contributes to drug resistance. FTY720 reduces P-gp overexpression, improving extracellular PHT levels by activating S1PR1. These findings suggest FTY720 may be an inhibitor of seizure-induced P-gp overexpression. Because FTY720 has been used in the clinic, further studies should clarify the effects of FTY720 on P-gp in drug-resistant epilepsy.
In summary, our results suggest FTY720 inhibits the seizure-induced overexpression of P-gp and improves brain delivery of PHT in rat hippocampus. This beneficial effect may result from suppression of NF-jB signalling and its downstream inflammatory mediators, TNF-a and COX-2, by activating S1PR1. Our study suggests that FTY720 offers a clinically useful therapeutic option in patients with refractory epilepsy. Fig. 6 . FTY720 strengthens extracellular PHT concentration in hippocampus of SE rats. PHT concentrations in plasma and hippocampal dialysate were measured 48 hr after SE, using HPLC. Data are mean AE S.E.M. at 30, 60, 90, 120 and 180 min. after PHT administration (50 mg/kg i.p.) in plasma (A) and dialysate (B). n = 5; * p < 0.05 versus SE + FTY (repeated-measures two-way ANOVA followed by Tukey's test).
